{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021996","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.965751+00:00","generated_at":"2026-06-15T01:17:12.847509+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ARS Pharma neffy FDA Panel Vote 'Favorable'; Q1 Net Loss $15.0M, Cash $264.5M","bullets":["FDA advisory committee voted 16:6 (adults) and 17:5 (children) that neffy benefit-risk is favorable.","PDUFA target action date anticipated mid-2023; NDA and MAA under review in US and EU.","Cash $264.5M, sufficient for at least three years including planned neffy launch.","Net loss $15.0M for Q1 2023; R&D $6.6M, G&A $12.2M.","Commercial launch prep underway with planned 125-person salesforce."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021996","json":"https://secwatch.observer/filing/0000950170-23-021996.json","markdown":"https://secwatch.observer/filing/0000950170-23-021996.md","text":"https://secwatch.observer/filing/0000950170-23-021996.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000095017023021996/0000950170-23-021996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000095017023021996/spry-20230515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:17:12.847509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ca9408edaac5d212c3bf368cc510c11caf94a31","claim":"ARS Pharmaceuticals, Inc. reported the quarter ended March 31, 2023 results: net income $15.0 million.","evidence_excerpt":"Net loss was $15.0 million for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000095017023021996/0000950170-23-021996-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"$15.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}